Kiniksa Pharmaceuticals International, plc (KNSA): restructuring charge — Kiniksa Q4 ARCALYST rev $122.5M ($417M FY); guides 2025 $560-580M; discontinues mavrilimumab & abiprubart

Kiniksa Pharmaceuticals International, plc

2024-FY EPS reported -$0.60 revenue$423,239,000

ARCALYST Q4 net product revenue $122.5M; full year $417.0M (79% YoY growth).
2025 ARCALYST revenue guidance $560-580M; expects annual cash flow positive.
Terminated MedImmune license for mavrilimumab; effective May 22, 2025.
Discontinued abiprubart Phase 2b trial in Sjögren's Disease; expects $14-17M additional expenses.
Net loss Q4 $8.9M (vs net income $25.2M); full year net loss $43.2M (vs net income $14.1M).

item 1.02 item 2.02 item 2.05 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Kiniksa Pharmaceuticals International, plc announced a restructuring with charges of approximately $19 million in expenses and expects to record approximately $14 million to $17 million in additional expenses affecting Phase 2b clinical trial of abiprubart in Sjögren’s Disease.

Type: restructuring
Charge: approximately $19 million in expenses and expects to record approximately $14 million to $17 million in additional expenses
Affected area: Phase 2b clinical trial of abiprubart in Sjögren’s Disease

Exact text from the filing

completion of winddown activities expected to occur by the end of 2025. As a result of the termination of the Phase 2b clinical trial, the Company has incurred approximately $19 million in expenses and expects to record approximately $14 million to $17 million in additional expenses, almost entirely consisting of expenses related to contract termination costs

View on SEC.gov

Browse all restructurings & charges →

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001104659-25-016725

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.